Authors

• Michael R. Hamblin (ORCID: https://orcid.org/0000-0001-6431-4605)
• Luca Richeldi (ORCID: https://orcid.org/0000-0001-8594-1448)
• Toby M. Maher (ORCID: https://orcid.org/0000-0001-7192-9149)
• Claudia Valenzuela (ORCID: https://orcid.org/0000-0002-0856-6290)
• Wim Wuyts (ORCID: https://orcid.org/0000-0001-9648-3497)
• Brandon Elpers
• Sinae Kim (ORCID: https://orcid.org/0000-0002-9900-492X)
• Michael Kreuter
• Aditya Patel

Institutions

• Università Cattolica del Sacro Cuore (IT)
• Johannes Gutenberg University Mainz (DE)
• Bristol-Myers Squibb (United States) (US)
• University Medical Center of the Johannes Gutenberg University Mainz (DE)
• Lung Institute (US)
• University of Kansas Medical Center (US)
• Hospital Universitario de La Princesa (ES)
• KU Leuven (BE)

Publication Details

Journal

CHEST Journal

Published

2025-04-08

DOI

https://doi.org/10.1016/j.chest.2025.04.003

Citations

1

Primary Topic

Pulmonary Hypertension Research and Treatments

Type

article

Field-Weighted Citation Impact

1.52

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Gilead Sciences
• Biogen
• Celgene
• FibroGen
• Chiesi Farmaceutici
• CSL Behring
• Galecto
• Veracyte
• Deutsche Forschungsgemeinschaft
• Bundesministerium für Bildung und Forschung
• Uniklinikum Giessen und Marburg
• Deutsches Zentrum für Lungenforschung
• Medac